News | January 14, 2009

Doctors Request More Funding for Imaging Prostate Cancer

January 14, 2009 – Leaders from the medical field and academia urge Obama Administration, Congress, the National Institutes of Health and the Department of Defense to increase federal funding for research into imaging technologies for less invasive and more accurate diagnosis of prostate cancer.

“We lack the accurate imaging tools that would help us perform better biopsies and design more optimal treatments for our patients,” said Theodore DeWeese, M.D., chair of Radiation Oncology at Johns Hopkins University, who was among the conference participants to support the consensus statement.

Meeting this week in Bethesda, MD, at a conference convened by the AdMeTech Foundation, the medical experts discussed strategies for speeding development of imaging technologies for prostate cancer modeled after life-saving mammograms for women. They reportedly agreed that advanced prostate imaging would save lives and an estimated $5 billion per year in healthcare costs.

“As physicians, scientists, educators and patients, we are personally concerned about the human and societal costs of prostate cancer. We firmly believe that more accurate imaging technology would lead to better patient care, including guidance for diagnosis, biopsy and minimally invasive therapy,” today’s consensus statement reads. “The AdMeTech Foundation conference clearly demonstrated that real and important improvements in prostate cancer care are at hand if we are resolved to increase the national investment in prostate diagnostics.”

Conference participants also signed a letter to Dr. Raynard S. Kington, acting director of the National Institutes of Health, urging increased federal research funding for prostate cancer imaging diagnostics.

The clinical experts met over the past two days as a result of the meeting between leadership of the AdMeTech Foundation, advocacy groups, and industry with Dr. Elias Zerhouni, director of NIH, in the spring of 2008. The experts unanimously agreed that prostate cancer care is in a state of crisis due to the lack of reliable imaging tools critical to guiding early detection, accurate diagnosis and the most effective and least invasive treatment.

For more information: www.admetech.org

Related Content

Bruker Introduces New High-Performance Preclinical PET/CT Si78 System
Technology | PET-CT | September 26, 2018
September 26, 2018 — Bruker recently announced the introduction of the new preclinical...
Siemens Healthineers Announces FDA Clearance of syngo.via VB30 Molecular Imaging Software
Technology | Nuclear Imaging | July 16, 2018
At the 2018 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), June 23-26 in Philadelphia...
Philips North America and GE Healthcare Win IMV PET Imaging ServiceTrak Awards
News | PET Imaging | June 25, 2018
IMV, part of the Science and Medicine Group and a market research and business intelligence provider to the imaging...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
News | Radiopharmaceuticals and Tracers | May 09, 2018
Blue Earth Diagnostics signed an exclusive, worldwide agreement with Scintomics GmbH, Germany, a specialist in...
In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...